Xu Ying, Zhang Han-Ting, O'Donnell James M
Departments of Behavioral Medicine & Psychiatry, Neurobiology & Anatomy, and Physiology & Pharmacology and the WVU Center for Neuroscience, West Virginia University Health Sciences Center, WVU HSC/School of Medicine, Morgantown, 9104, WV 26506, USA.
Handb Exp Pharmacol. 2011(204):447-85. doi: 10.1007/978-3-642-17969-3_19.
Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes that are involved in the regulation of the intracellular second messengers cyclic AMP (cAMP) and cyclic GMP (cGMP) by controlling their rates of hydrolysis. There are 11 different PDE families and each family typically has multiple isoforms and splice variants. The PDEs differ in their structures, distribution, modes of regulation, and sensitivity to inhibitors. Since PDEs have been shown to play distinct roles in processes of emotion and related learning and memory processes, selective PDE inhibitors, by preventing the breakdown of cAMP and/or cGMP, modulate mood and related cognitive activity. This review discusses the current state and future development in the burgeoning field of PDEs in the central nervous system. It is becoming increasingly clear that PDE inhibitors have therapeutic potential for the treatment of neuropsychiatric disorders involving disturbances of mood, emotion, and cognition.
环核苷酸磷酸二酯酶(PDEs)是一类超家族酶,通过控制细胞内第二信使环磷酸腺苷(cAMP)和环磷酸鸟苷(cGMP)的水解速率来参与它们的调节。有11个不同的PDE家族,每个家族通常有多个亚型和剪接变体。PDEs在结构、分布、调节方式和对抑制剂的敏感性方面存在差异。由于PDEs已被证明在情绪过程以及相关学习和记忆过程中发挥着不同的作用,选择性PDE抑制剂通过阻止cAMP和/或cGMP的分解来调节情绪和相关认知活动。本文综述了中枢神经系统中新兴的PDEs领域的现状和未来发展。越来越清楚的是,PDE抑制剂在治疗涉及情绪、情感和认知障碍的神经精神疾病方面具有治疗潜力。